Detalhe da pesquisa
1.
Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.
Bioorg Med Chem Lett
; 23(12): 3565-9, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23664880
2.
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
Bioorg Med Chem Lett
; 23(5): 1486-92, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23352510
3.
Discovery of a novel series of 4-quinolone JNK inhibitors.
Bioorg Med Chem Lett
; 22(24): 7381-7, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23142618
4.
Discovery of potent and bioavailable GSK-3beta inhibitors.
Bioorg Med Chem Lett
; 20(5): 1693-6, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20138512
5.
Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.
J Med Chem
; 57(5): 1914-31, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24195700
6.
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.
J Med Chem
; 56(4): 1677-92, 2013 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23350847
7.
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
J Med Chem
; 54(7): 2255-65, 2011 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-21375264